125 related articles for article (PubMed ID: 38630996)
1. High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma.
Al-Ward R; Brondani VB; Sawani S; Potter CL; Xu G; Waguespack SG; Varghese J; Habra MA; Lu Y; Jimenez C
Clin Nucl Med; 2024 Jul; 49(7):610-620. PubMed ID: 38630996
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of High-Specific-Activity
Pryma DA; Chin BB; Noto RB; Dillon JS; Perkins S; Solnes L; Kostakoglu L; Serafini AN; Pampaloni MH; Jensen J; Armor T; Lin T; White T; Stambler N; Apfel S; DiPippo VA; Mahmood S; Wong V; Jimenez C
J Nucl Med; 2019 May; 60(5):623-630. PubMed ID: 30291194
[TBL] [Abstract][Full Text] [Related]
3. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
4. Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma.
Jimenez C; Chin BB; Noto RB; Dillon JS; Solnes L; Stambler N; DiPippo VA; Pryma DA
Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36472300
[TBL] [Abstract][Full Text] [Related]
5. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
[TBL] [Abstract][Full Text] [Related]
6. False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
Fonte JS; Robles JF; Chen CC; Reynolds J; Whatley M; Ling A; Mercado-Asis LB; Adams KT; Martucci V; Fojo T; Pacak K
Endocr Relat Cancer; 2012 Feb; 19(1):83-93. PubMed ID: 22167067
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
[TBL] [Abstract][Full Text] [Related]
8. Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131 I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma.
Jimenez C; Lu Y
Clin Nucl Med; 2023 May; 48(5):426-427. PubMed ID: 36728291
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S
J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma.
Noto RB; Pryma DA; Jensen J; Lin T; Stambler N; Strack T; Wong V; Goldsmith SJ
J Clin Endocrinol Metab; 2018 Jan; 103(1):213-220. PubMed ID: 29099942
[TBL] [Abstract][Full Text] [Related]
11. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre.
Rutherford MA; Rankin AJ; Yates TM; Mark PB; Perry CG; Reed NS; Freel EM
QJM; 2015 May; 108(5):361-8. PubMed ID: 25267727
[TBL] [Abstract][Full Text] [Related]
12. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
Gedik GK; Hoefnagel CA; Bais E; Olmos RA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
[TBL] [Abstract][Full Text] [Related]
13. Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma.
Wakabayashi H; Taki J; Inaki A; Nakamura A; Kayano D; Fukuoka M; Matsuo S; Nakajima K; Kinuya S
Ann Nucl Med; 2013 Nov; 27(9):839-46. PubMed ID: 23864328
[TBL] [Abstract][Full Text] [Related]
14. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
[TBL] [Abstract][Full Text] [Related]
15. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
16. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
17. [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():778322. PubMed ID: 35197929
[TBL] [Abstract][Full Text] [Related]
18. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [
Inaki A; Shiga T; Tsushima Y; Jinguji M; Wakabayashi H; Kayano D; Akatani N; Yamase T; Kunita Y; Watanabe S; Hiromasa T; Mori H; Hirata K; Watanabe S; Higuchi T; Tomonaga H; Kinuya S
Ann Nucl Med; 2022 Mar; 36(3):267-278. PubMed ID: 34870794
[TBL] [Abstract][Full Text] [Related]
19. 131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours - a single-centre study.
Kotecka-Blicharz A; Hasse-Lazar K; Handkiewicz-Junak D; Gawlik T; Pawlaczek A; Oczko-Wojciechowska M; Michalik B; Szpak-Ulczok S; Krajewska J; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2018; 69(3):246-251. PubMed ID: 29645065
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical trial for [
Wakabayashi H; Inaki A; Yoshimura K; Murayama T; Imai Y; Higuchi T; Jinguji M; Shiga T; Kinuya S
Sci Rep; 2019 May; 9(1):7625. PubMed ID: 31110198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
